![](https://danskbiotek.dk/wp-content/uploads/2019/02/Vaccibody-image-300x65.png)
Vaccibody AS – NOK 230 million (EUR 23.6 million) private placement successfully placed 19 February 2019
Oslo, 14 February 2019 Reference is made to the press release by Vaccibody AS (“Vaccibody”... Read more
Oslo, 14 February 2019 Reference is made to the press release by Vaccibody AS (“Vaccibody”... Read more
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
MinervaX, a privately held Danish biotech company, announces today that is has been awarded an in... Read more
This free ELIXIR Innovation and SME Forum with a focus on Genomics and Associated Data in Nationa... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement... Read more
The Nordic countries have launched an ambitious plan to fast-track the development of a sustainable bioeconomy... Read more